Quidel Co. (NASDAQ:QDEL) CFO Randall J. Steward sold 39,103 shares of the stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $67.50, for a total transaction of $2,639,452.50. Following the completion of the transaction, the chief financial officer now owns 58,562 shares of the company’s stock, valued at approximately $3,952,935. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of NASDAQ QDEL opened at $65.56 on Friday. The stock has a market capitalization of $2.67 billion, a P/E ratio of 23.25, a price-to-earnings-growth ratio of 0.98 and a beta of 1.27. Quidel Co. has a 52 week low of $41.97 and a 52 week high of $77.63. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.86 and a current ratio of 1.21.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, February 13th. The company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.21. The firm had revenue of $132.59 million for the quarter, compared to analysts’ expectations of $132.26 million. Quidel had a net margin of 14.20% and a return on equity of 31.73%. The firm’s revenue was up 15.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.56 EPS. As a group, equities research analysts expect that Quidel Co. will post 2.77 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Quidel by 5.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,929,387 shares of the company’s stock valued at $190,909,000 after acquiring an additional 152,702 shares during the last quarter. Vanguard Group Inc grew its stake in Quidel by 5.5% in the 3rd quarter. Vanguard Group Inc now owns 2,929,387 shares of the company’s stock valued at $190,909,000 after acquiring an additional 152,702 shares during the last quarter. BlackRock Inc. grew its stake in Quidel by 0.6% in the 4th quarter. BlackRock Inc. now owns 2,304,494 shares of the company’s stock valued at $112,504,000 after acquiring an additional 12,840 shares during the last quarter. Macquarie Group Ltd. grew its stake in Quidel by 15.9% in the 3rd quarter. Macquarie Group Ltd. now owns 963,519 shares of the company’s stock valued at $62,792,000 after acquiring an additional 131,980 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Quidel by 2.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 861,159 shares of the company’s stock valued at $42,041,000 after acquiring an additional 17,041 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.
QDEL has been the subject of a number of research analyst reports. ValuEngine downgraded shares of Quidel from a “hold” rating to a “sell” rating in a report on Friday, December 7th. Zacks Investment Research downgraded shares of Quidel from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub upgraded shares of Quidel from a “hold” rating to a “buy” rating in a report on Saturday, January 12th. Finally, Barclays reiterated a “buy” rating and issued a $74.00 price target on shares of Quidel in a report on Friday, February 15th. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Quidel presently has a consensus rating of “Buy” and a consensus price target of $71.50.
ILLEGAL ACTIVITY NOTICE: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://transcriptdaily.com/2019/03/01/randall-j-steward-sells-39103-shares-of-quidel-co-qdel-stock.html.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.